Imperagen

The firm is developing an ultra-fast enzyme engineering platform called Digital Enzyme Evolution™ to accelerate the design and optimization of novel enzymes. This proprietary technology integrates artificial intelligence, machine learning, synthetic biology, and laboratory automation. By combining AI-led protein design with robotics, the platform aims to create high-performance enzymes with improved speed and accuracy, reducing development timelines from months to weeks. This addresses the costly, labor-intensive, and unpredictable nature of traditional enzyme development.

Imperagen serves diverse markets, including pharmaceutical manufacturing, life sciences, and sustainable chemical production. Its initial focus is on developing enzyme products for the manufacture of complex drug molecules, with a long-term goal of expanding into applications like enzyme replacement therapies and drug delivery systems. The business model involves collaborating with customers to de-risk and streamline their product development. In August 2022, Imperagen secured a £3.5 million ($4.2M) seed funding round led by IQ Capital and Northern Gritstone to advance its platform development and validation.